ECOR vs NVCR vs INVA vs ABT

For growth investors, electroCore, Inc.

(ECOR) is the stronger pick with 27. 2% revenue growth year-over-year, versus 4. 6% for Abbott Laboratories (ABT). Innoviva, Inc. (INVA) offers the better valuation at 6. 9x trailing P/E (11. 9x forward), making it the more compelling value choice. Analysts rate NovoCure Limited (NVCR) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Innoviva, Inc.

(INVA) is the cheapest at 6. 9x versus Abbott Laboratories at 11. 4x. On forward P/E, Innoviva, Inc. is actually cheaper at 11. 9x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Abbott Laboratories wins at 0. 53x versus Innoviva, Inc. 's 1. 15x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Innoviva, Inc.

(INVA) delivered a total return of +94. 4%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: ABT returned +173. 7% versus ECOR's -97. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Innoviva, Inc.

(INVA) is the lower-risk stock at 0. 13β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 1648% more volatile than INVA relative to the S&P 500. On balance sheet safety, Innoviva, Inc. (INVA) carries a lower debt/equity ratio of 23% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), electroCore, Inc.

(ECOR) is pulling ahead at 27. 2% versus 4. 6% for Abbott Laboratories (ABT). On earnings-per-share growth, the picture is similar: Innoviva, Inc. grew EPS 816. 7% year-over-year, compared to -3. 8% for electroCore, Inc.. Over a 3-year CAGR, ECOR leads at 55. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Innoviva, Inc.

(INVA) is the more profitable company, earning 63. 8% net margin versus -43. 6% for electroCore, Inc. — meaning it keeps 63. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INVA leads at 38. 5% versus -41. 1% for ECOR. At the gross margin level — before operating expenses — ECOR leads at 86. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Abbott Laboratories (ABT) is the more undervalued stock at a PEG of 0. 53x versus Innoviva, Inc. 's 1. 15x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Innoviva, Inc. (INVA) trades at 11. 9x forward P/E versus 15. 9x for Abbott Laboratories — 4. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVCR: 99. 0% to $33. 50.

In this comparison, ABT (2.

5% yield) pays a dividend. ECOR, NVCR, INVA do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Abbott Laboratories (ABT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

25), 2. 5% yield, +173. 7% 10Y return). electroCore, Inc. (ECOR) carries a higher beta of 2. 06 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ABT: +173. 7%, ECOR: -97. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ECOR is a small-cap high-growth stock; NVCR is a small-cap quality compounder stock; INVA is a small-cap high-growth stock; ABT is a mid-cap deep-value stock. ABT pays a dividend while ECOR, NVCR, INVA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.